The triple co-agonist showed similar safety and tolerability profile to other incretins and led to placebo-adjusted reduction in HbA1C of up to 1.56% and to placebo-adjusted weight reduction of up to 8.96 kg.135 Further trials in larger populations of people with T2D and obesity are required to confirm the therapeutic potential of GLP-1/GIP/glucagon receptor triagonists. This evidence concerns the gene GCG and type 2 diabetes mellitus.